Drug
Alxn2230
Alxn2230: highest development phase Phase 1, developed by Alexion. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Alexion
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALXN2230 NCT07352423 | Phase 1 |
Latest
No recent events.
Follow Alxn2230 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.